A
AbCellera Biologics Inc. (ABCL)
NMS – Real vaqt narxi. Valyuta: USD
7.38
+0.72 (10.81%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
Bozordan keyin: Jun 26, 2026, 7:58 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
7.38
+0.72 (10.81%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
Bozordan keyin: Jun 26, 2026, 7:58 PM EDT
AbCellera Biologics Inc. Amerika Qo'shma Shtatlarida tibbiy ehtiyojlari qondirilmagan ko'rsatkichlar uchun antitelalarga asoslangan dori-darmonlarni kashf qilish va ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsuloti ABCL635 bo'lib, bu gormon bo'lmagan dori, u o'rtacha va og'ir vazomotor simptomlarni davolash uchun 2-bosqich klinik sinovida; va ABCL575, to'liq inson, yarim umri uzaytirilgan monoklonal antitelasi, u atopik dermatit kabi T-hujayrali autoimmun kasalliklarni davolash uchun 1-bosqich klinik sinovida. Kompaniya Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc bilan T-hujayrali (TCE) ko'p o'ziga xos antitelalarni ishlab chiqish bo'yicha ilmiy hamkorlik va litsenziyalash shartnomasiga ega; va Viking Global Investors & ArrowMark Partners va Biogen Inc. bilan hamkorlik shartnomasiga ega. AbCellera Biologics Inc. 2012 yilda tashkil etilgan va shtab-kvartirasi Vankuver, Kanadada joylashgan.
| Ism | Lavozim |
|---|---|
| Caitlin Webster CIPD, M.Sc. | Director of Talent Development |
| Dr. Carl L.G. Hansen Ph.D. | CEO, President & Chairperson |
| Dr. Veronique Lecault Ph.D. | CTO & Director |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer |
| Mr. Andrew Knowles M.Sc. | Vice President of Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-17 | 8-K | abcl-20260617.htm |
| 2026-06-12 | 8-K | abcl-20260611.htm |
| 2026-06-05 | 8-K | abcl-20260601.htm |
| 2026-05-11 | 8-K | abcl-20260511.htm |
| 2026-05-11 | 10-Q | abcl-20260331.htm |
| 2026-04-29 | DEFA14A | defa14a.htm |
| 2026-04-29 | DEF 14A | abcl-20260429.htm |
| 2026-04-29 | ARS | annualreport.pdf |
| 2026-02-24 | S-8 | abcellera-formsx82026.htm |
| 2026-02-24 | 8-K | abcl-20260224.htm |
| Mr. Martin Hogan M.Sc. | Senior Director of Strategic Finance & IR |
| Mr. Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer |
| Ms. Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications |